⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
LLY News
Eli Lilly & Co.
Refills GLP-1 Weight Loss Guide 2026: Branded vs Compounded Options, Eligibility, Pricing Factors, and FDA Safety Notes
accessnewswire.com
NVO
LLY
SkinnyRx GLP-1 Weight Loss Guide 2026: Injectable vs Sublingual vs Tablet Options (Semaglutide + Tirzepatide)
accessnewswire.com
NVO
LLY
Defiance ETFs Announces Closure of Select Funds
globenewswire.com
D
PLT
SMCC
HOOI
ETHI
AMDU
HIMY
TRIL
PLTR
SMCI
HOOD
HIMS
LLY
Liberty All-Star® Growth Fund, Inc. December 2025 Monthly Update
businesswire.com
ASG
NVDA
AAPL
MSFT
GOOGL
AMZN
META
OLLI
NTRA
LLY
CW
SMTC
ACAD
IDXX
ROST
CRM
BAH
CYBR
SPOT
SPSC
TTC
TDG
Oral Protein and Peptides Market to Hit Valuation of US$ 47.33 Billion By 2035 | Astute Analytica
globenewswire.com
VKTX
LLY
NVO
MRK
FSK
TSN
KDP
PEP
MNDO
THG
ENTX
RANI
Digbi Health Publishes Peer-Reviewed Data Demonstrating Significant Cost Savings for Employers Via Its Precision Biology Telehealth Platform to Manage GLP-1, Metabolic, and GI Costs
globenewswire.com
NVO
LLY
House Dust Mite Disease Market to Exhibit Substantial Growth at a CAGR of 3.5% During the Forecast Period (2025-2034) | DelveInsight USA - English USA - English
prnewswire.com
ALKS
STG
GSK
SNY
TEVA
AZN
INCY
REGN
PFE
BMY
LLY
AMGN
ABBV
GILD
BIIB
CSL
VRTX
BHC
NVS
MRK
LEO
ALLT
CNTB
INM
Flashpoint Therapeutics Appoints Venkat R. Krishnamurthy, Ph.D. as Chief Scientific Officer
businesswire.com
LLY
AZN
XCUR
Strive Compounding Pharmacy Files Landmark Antitrust Lawsuit Against Eli Lilly and Novo Nordisk
prnewswire.com
LLY
NVO
Peptide Therapeutics Market Report 2025-2035: Industry to Experience Robust Growth with a CAGR of 6.8% Through 2035 - Subcutaneous Route to Command Over 65% Share - ResearchAndMarkets.com
businesswire.com
APLS
BLRX
LLY
NTRA
NVO
PLTK
ZBRA